Introduction
============

Heart failure (HF) is the leading cause of death and hospitalization in industrialized countries, and covers an important part of the health care costs.[@b1-cmc-8-2014-039]--[@b3-cmc-8-2014-039] In recent years, the introduction of new drugs and the use of devices has reduced mortality rates;[@b4-cmc-8-2014-039] however, the hospitalization rates continue to increase and the prognosis still remains unsatisfactory with high mortality and readmission rates.[@b5-cmc-8-2014-039]--[@b7-cmc-8-2014-039] The growing acknowledge regarding metabolic abnormalities, hypercatabolic status, and cachexia in HF and their impact on outcomes have contributed to consider HF as a cardiac and whole body metabolic disease, which may be the final pathway of the hemodynamic abnormalities and the neurohormonal and inflammatory activation.[@b8-cmc-8-2014-039] Several macro and micronutrients deficiencies have been recognized in HF and lead to a disruption in energy as well as in anabolic metabolism. Among micronutrients, amino acids (AAs) act in both these metabolic pathways as intermediary for energy production and transfer and as main constituents of proteins.[@b9-cmc-8-2014-039] The aim of our study was to evaluate the effects of the administration of a mixture of 11 AAs on functional capacity expressed by the improvement in cardiopulmonary stress test parameters and six minutes walking test (6MWT) distance. The secondary endpoints were to evaluate the effects on quality of life and NT-proBNP levels in a population of ambulatory patients with chronic HF.

Methods
=======

Patients
--------

We recruited 13 consecutive patients with stable chronic HF because of dilated cardiomyopathy without coronary disease. All patients were symptomatic for HF for ≥6 months in NYHA class II or III, with an ejection fraction (EF) \<45% by echocardiography or radionuclide ventriculography (RVG), and able to perform a cardiopulmonary exercise test with a peak VO~2~ ≥10 mL/kg/minute. Patients were on optimal medical therapy, treated with angiotensin-converting-enzyme inhibitor (ACE) or angiotensin-receptor blocker and beta-blockers at a stable dose for at least four weeks before entering in the study. Patients were excluded if they had ischemic-dilated cardiomyopathy, symptoms of myocardial ischemia, acute coronary syndromes, or a coronary revascularization procedure in the previous three months; implantation of a cardiac resynchronization therapy (CRT) device in the prior six months or likely to receive implantation in the next three months; history of severe valvular disease (with the exception of functional mitral regurgitation); congenital heart disease, acute myocarditis, and hypertrophic or restrictive cardiomyopathy; cerebrovascular events or major surgery in the previous six months; and any concomitant disease that might adversely impair the exercise performance or the prognosis of the patient. The investigation conformed to the principles outlined in the Declaration of Helsinki. The study received ethical approval from the Department of Cardiology, University of Brescia, and all patients gave their written, informed consent to participate.

Study protocol
--------------

A prospective, open study evaluated the efficacy of the administration of a mixture of essential and semi-essential AAs in patients with stable chronic HF. Patients were evaluated at baseline and after a three months follow-up. Each patient underwent clinical assessment, maximal cardiopulmonary exercise test, 6MWT, transthoracic echocardiogram, RVG or cardiac magnetic resonance imaging (MRI), and Minnesota Living with Heart Failure Questionnaire (MLHFQ) before initiation of AAs administration and after three months. Each patient followed habitual daily diet. Cardiopulmonary stress test was performed with a cycloergometer with expiratory gas exchange and ECG monitoring, starting with a workload of 20 W with increments of 10 W/minute. All patients performed two preliminary cardiopulmonary tests before the baseline evaluation to be familiar with the procedure with a variability less than 10% in peak VO~2~ between the screening tests. A maximal exercise was defined as reaching a respiratory exchange ratio (RER) ≥1.10. Peak VO~2~ was measured at the maximal exercise as the average value in the last 30 seconds of exercise.

Patients received for three months a mixture of essential and semi-essential AAs (L-leucine, L-lysine, L-isoleucine, L-valine, L-threonine, L-cystine, L-hystidine, L-phenylalanine, L-methionine, L-tyrosine, L-tryptophan; the composition is outlined in [Table 1](#t1-cmc-8-2014-039){ref-type="table"}), thiamine, and pyridoxine (Aminotrofic^®^, Professional Dietistic, Milan, Italy), at the dose of 4 g twice a day, diluted with water, at 10:00 AM and 4:00 PM.

The primary endpoint was to evaluate the effects of AAs supplementation on exercise tolerance at cardiopulmonary stress test and 6MWT. The secondary endpoints were to evaluate the effects on quality of life and NT-proBNP levels.

Echocardiographic analysis
--------------------------

Echocardiography examinations were performed by experienced operators in accordance with the recommendations of the European Society of echocardiography[@b10-cmc-8-2014-039] using a Vivid Seven (GE Healthcare, UK) system operating at 3.4 MHz. Doppler tracings and two-dimensional images were obtained from parasternal long- and short-axes, apical, and subcostal views. Two-dimensional guided M-mode measurements of left ventricle's (LV's) internal dimensions, and septum and posterior wall thicknesses were made at the LV minor axis. Left ventricular ejection fraction (LVEF) was measured using Simpson's biplane method.

Statistical analysis
--------------------

Categorical data are presented as percentages, normally distributed continuous data as mean ± standard deviation (SD), and non-normally distributed variables as median and interquartile range. Comparisons were made with paired Student's *t*-test for continuous variables and chi-squared test for categorical variables as appropriate. For the statistical analysis, we used the SPSS version 19.0.1 (SPSS Inc., Chicago, IL), and a two-sided *P*-value ≤0.05 was considered statistically significant.

Results
=======

Characteristics of patients
---------------------------

Baseline characteristics of the patients are outlined in [Table 2](#t2-cmc-8-2014-039){ref-type="table"}. We enrolled 13 patients, and all patients reached the end of the study after a follow-up of three months. The mean age was 59 ± 14 years, and 11 (84.6%) patients were male. All patients were treated with ACE inhibitors and/or ARBs and beta-blockers at baseline, and the treatment did not change significantly during the follow-up period. Renal function was normal or mildly reduced at baseline (serum creatinine 1.0 ± 0.3 mg/dL, estimated glomerular filtration rate 88.8 ± 27.6 mL/minute/m^2^), and NT-proBNP levels were elevated 1502 ± 1900 ng/L in agreement with other studies in ambulatory patients with HF.[@b11-cmc-8-2014-039] Echocardiographic and functional capacity data at baseline and follow-up are outlined in [Table 3](#t3-cmc-8-2014-039){ref-type="table"}. All patients had a moderate to severe LV dysfunction with an EF 29.0 ± 7.9% by echocardiography and dilated LV demonstrated with an end diastolic diameter (EDD) 7.3 ± 1.0 mm and end diastolic volume index (EDVI) 107.2 ± 34.6 mL. Data regarding LV function evaluated by echocardiography were consistent with the equilibrium RVG or cardiac MRI measurements, which estimated an EF of 30.1 ± 9.2% at baseline. The functional capacity, assessed with cardiopulmonary stress test, was reduced at baseline with a peak VO~2~ of 14.8 ± 3.9 mL/minute/kg. During the treatment period, no adverse effects have been documented by either relevant medical history or laboratory values' abnormalities. No patient died or has been rehospitalized during the study.

Treatment effects
-----------------

After three months treatment with AAs supplement, the EF and the other echocardiographic parameters did not change significantly: EF (baseline 29.0 ± 7.9% vs follow-up 30.8 ± 9.1%; *P* = 0.095) and EDD (baseline 7.3 ± 1.0 mm vs follow-up 7.2 ± 0.9 mm; *P* = 0.212). A trend in the reduction of EDVI (baseline 107.2 ± 34.6 mL vs follow-up 99.2 ± 34.3 mm; *P* = 0.071) was observed. Compared with baseline, peak VO~2~ (baseline 14.8 ± 3.9 mL/minute/kg vs follow-up 16.8 ± 5.1 mL/minute/kg; *P* = 0.008) and VO~2~ at anaerobic threshold improved significantly (baseline 9.0 ± 3.8 mL/minute/kg vs follow-up 12.4 ± 3.9 mL/minute/kg; *P* = 0.002) ([Figs. 1](#f1-cmc-8-2014-039){ref-type="fig"} and [2](#f2-cmc-8-2014-039){ref-type="fig"}). Also the 6MWT distance increased at three months (baseline 439.1 ± 64.3 m vs follow-up 474.2 ± 89.0 m; *P* = 0.006) ([Fig. 3](#f3-cmc-8-2014-039){ref-type="fig"}). The perception of symptoms and quality of life evaluated with the MLHFQ did not change significantly compared with baseline (baseline 21 ± 14 vs follow-up 25 ± 13; *P* = 0.321). A non-significant trend in the reduction of NT-proBNP levels was observed at follow-up (baseline 1502 ± 1900 ng/L vs follow-up 1040 ± 1345 ng/L; *P* = 0.052).

Discussion
==========

In recent years, many studies focused on the macro- and micronutrient deficiencies in HF and their contribution to the pathophysiology and progression of the cardiac dysfunction that eventually leads to a reduction in exercise tolerance and quality of life. The AAs play a prominent role in this setting.[@b9-cmc-8-2014-039],[@b12-cmc-8-2014-039] Patients with HF develop progressively a hypercatabolic state that results in advanced stages in cardiac cachexia.[@b13-cmc-8-2014-039] These abnormalities in cardiac and whole body metabolism are related to the poor absorption of nutrients by the congested bowel wall; by the activation of local and systemic inflammatory response; by the neurohormonal abnormalities, such as sympathetic and RAAs activation; and by the prevalence of catabolic hormones. The final effect is a gradual release of the AAs stored in the skeletal muscle and their transformation through the liver into glucose that is used as a energy source in the heart and in the other glucose-dependent organs, namely the brain. The continuous release of AAs from the skeletal muscle leads to a progressive loss in muscle bulk and thus a reduction in exercise performance. In patients with HF there is a shift in skeletal muscle fibers' type from the "red fibers" that are more efficient in energy utilization compared to "white fibers" that are more dependent on the glycolysis. In the failing heart the increase of read fibers promotes the release of lactic acid that contributes to exercise intolerance and early fatigue. Eventually, the patients with HF develop a deficit of AAs that are necessary for the failing heart as a energy source and for protein synthesis, which results in the progression of the disease.[@b14-cmc-8-2014-039] Thus, in recent years many studies investigated the possible favorable role of AAs supplementation in HF. Almost all those studies have a positive result in terms of increase in exercise tolerance and quality of life, although many of them were conducted with the supplementation of one or few molecules. In the first study, Azuma and colleagues showed that supplementation of taurine in patients with chronic stable HF has favorable effects on symptoms.[@b15-cmc-8-2014-039],[@b16-cmc-8-2014-039] Subsequently, several studies have shown that supplementation of a single AA in patients with HF was able to improve the functional capacity. Mancini et al.[@b17-cmc-8-2014-039] observed in 60 patients affected by stable chronic HF that the supplementation of L-carnitine for six months improved the maximum exercise duration, and Anand et al.[@b18-cmc-8-2014-039] described 30 patients with HF in whom the supplementation of L-carnitine for one month improved peak VO~2~ and exercise duration. The major limitation of these early studies is the supplementation of a single type of AA. Furthermore, some AAs act as cofactors in many enzymatic reactions that have a key role in energy production. Most of them are essential AAs, namely AAs that cannot be synthesized and have to be introduced with the diet. However, an increase in protein intake with diet is not enough to counteract the AAs deficit.[@b19-cmc-8-2014-039] In this view, mixed AAs supplementation should be encouraged. In our study, we treated 13 patients with chronic stable HF, in NYHA class II--III with a mixture of essential and semi-essential AAs supplementation at the dose of 4 g twice a day. After three months of follow-up, exercise tolerance, evaluated as peak VO~2~, VO~2~ at anaerobic threshold and 6MWT distance improved. Moreover, we observed a trend in the reduction of EDV and of NT-proBNP levels. AAs treatment resulted well tolerated, without reported side effects or abnormalities in laboratory tests.

Our results are consistent with the previous studies. Aquilani et al.[@b20-cmc-8-2014-039] randomized in a double-blind fashion 95 patients with stable chronic HF in NYHA class II--III to essential AAs mixture (4 g twice daily) or placebo, and after one month of follow-up, observed a significant improvement in exercise capacity in the treatment with exercise maximal workload (*P* \< 0.01), duration (*P* \< 0.02) and peak VO~2~ (*P* \< 0.02). Similar results were obtained in another open label, placebo-controlled trial, which enrolled 15 stable chronic HF patients with EF \<40%. In the group treated with essential AAs mixture, they observed an improvement in the 6MWT distance.[@b21-cmc-8-2014-039]

In our study, the results of almost all the trials are promising, finding a positive association between mixed AAs supplementation and improvement in functional capacity, and resulted well tolerated and safe. Different from previous studies, we have analyzed a very heterogeneous mixture composed of 11 AAs. Our results encourage a wide range of micronutrient supplementation considering the serious depletion of macro- and micronutrients present in patients with HF.

Our study has some limitations, namely small sample size, the absence of a control group, and the short period of follow-up. Another major limitation is that in our study, we did not evaluate myocardial viability prior to AAs supplementation. This may be a confounding factor as muscle-depletion by itself and a more advanced stage of the disease are associated with a more pronounced exercise intolerance. Another limitation is the lack of plasma assay of a marker of muscle metabolism (eg, lactic acid) that could more accurately confirm the favorable effects of the mixture of AAs on the functional capacity.

In our study, supplementation with essential and semi-essential AAs for three months in patients with stable chronic HF improved exercise tolerance. However, it did not change symptoms' perception and quality of life and NT-proBNP levels. AAs treatment resulted safe and was well tolerated by all patients. We conclude that AAs supplementation may be a useful non-pharmacologic treatment, associated with conventional therapy, in patients with HF. Larger studies are needed to confirm these data and to investigate the potential benefits of AAs supplementation on the patients' outcomes.
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###### 

Nutritional composition of Aminotrofic^®^.

  AMINO ACID          
  ------------------- ---------
  Total amino acids   4 g
  L-Leucine           1250 mg
  L-Lysine            650 mg
  L-Isoleucine        625 mg
  L-Valine            625 mg
  L-Threonine         350 mg
  L-Cystine           150 mg
  L-Hystidine         150 mg
  L-Phenylalanine     100 mg
  L-Methionine        50 mg
  L-Tyrosine          30 mg
  L-Triptophan        20 mg

###### 

Baseline characteristics.

                                BASELINE (n = 13)   FOLLOW-UP (n = 13)   *P*-VALUE
  ----------------------------- ------------------- -------------------- -----------
  **Age---yr**                  59 ± 14                                  
  **Men---no. (%)**             11 (84.6)                                
  **SBP---mmHg**                121 ± 14            116 ± 12             0.172
  **DBP---mmHg**                75 ± 9              71 ± 9               0.160
  **Heart rate---bpm**          69 ± 13             67 ± 11              0\. 518
  **BMI---kg/m^2^**             25.7 ± 3.2          25.4 ± 2.8           0.316
  **Comorbidities---n (%)**                                              
  DM                            2 (15.4)                                 
  Hypertension                  6 (46.2)                                 
  Dyslipidemia                  7 (53.8)                                 
  Smoker                        3 (23.1)                                 
  Atrial fibrillation           3 (23.1)                                 
  COPD                          1 (7.7)                                  
  **Laboratory values**                                                  
  Creatinine---mg/dl            1.0 ± 0.3           1.0 ± 0.3            0.146
  eGFR---ml/min/m^2^            88.8 ± 27.6         84.2 ± 28.1          0.228
  Haemoglobin---g/dl            14.1 ± 1.6          13.1 ± 4.1           0.253
  Cholesterol---mg/dl           182 ± 34            165 ± 36             0.061
  Triglycerides---mg/dl         115 ± 63            97 ± 33              0.232
  CRP---u/l                     9.1 ± 24.9          1.6 ± 1.6            0.302
  NT-proBNP -- ng/l             1502 ± 1900         1040 ± 1345          0.052
  **Medications**---**n (%)**                                            
  Beta-blocker                  13 (100)                                 
  ACE inhibitor or ARB          13 (100)                                 
  Aldosterone antagonist        9 (69.2)                                 
  Loop diuretic                 10 (76.9)                                
  Statin                        5 (38.5)                                 

###### 

Echocardiographic and exercise capacity data.

                                                 BASELINE (n = 13)   FOLLOW-UP (n = 13)   *P*-VALUE
  ---------------------------------------------- ------------------- -------------------- -----------
  **Echocardiographic data**                                                              
  EDD---mm                                       7.3 ± 1.0           7.2 ± 0.9            0.212
  EDVI---ml                                      107.2 ± 34.6        99.2 ± 34.3          0.071
  IVS---mm                                       1.1 ± 0.2           1.1 ± 0.2            0.528
  EF---%                                         29.0 ± 7.9          30.8 ± 9.1           0.095
  TR gradient---mmHg                             34.9 ± 14.6         30.8 ± 5.7           0.202
  Mitral regurgitation (moderate to severe)      6 (46.2)            5 (38.5)             0.104
  Tricuspid regurgitation (moderate to severe)   3 (23.1)            1 (7.7)              0.277
  **EF by equilibrium RVG or MRI**               30.1 ± 9.2          31.7 ± 10.1          0.304
  **Cardiopulmonary stress test**                                                         
  Peak VO~2~---ml/min/Kg                         14.8 ± 3.9          16.8 ± 5.1           0.008
  VE/VCO~2~                                      37.1 ± 6.9          37.4 ± 7.7           0.754
  \% Peak VO~2~                                  54.0 ± 10.3         61.4 ± 13.7          0.061
  VO~2~ at AT- ml/min/Kg                         9.0 ± 3.8           12.4 ± 3.9           0.002
  RER                                            1.13 ± 0.09         1.04 ± 0.31          0.281
  Workload max---Watt                            100.9 ± 32.4        104.8 ± 28.4         0.380
  **6MWT**                                       439.1 ± 64.3        474.2 ± 89.0         0.006
  **MLHFQ score**                                21 ± 14             25 ± 13              0.321
